Promente Clinical Research Center
COMP 006 clinical trial
Sponsored by COMPASS Pathways.
Study purpose
COMP 006 is a clinical research study of a new approach to symptoms of treatment-resistant depression using COMP360, a synthetic form of psilocybin, together with psychological support.
What is COMP360?
COMP360 is a synthetic form of psilocybin. The study evaluates safety and efficacy in people whose depression has not responded sufficiently to standard antidepressant treatment.
Who may be eligible?
- Adults with diagnosed treatment-resistant depression.
- People for whom at least two antidepressant medicines have not provided sufficient improvement.
- Final eligibility is assessed by the study physician during screening.
Ask about COMP 006
Eligibility depends on medical assessment and protocol criteria.